Nitrazepam

Quick links to important sections

Nitrazepam

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitrazepam

Nitrazepam is a synthetic pharmaceutical compound that belongs to the class of 1,4-benzodiazepine derivatives, primarily functioning as a potent central nervous system (CNS) depressant. It is manufactured as a single-active-ingredient medication, exclusively containing Nitrazepam as its active component, which is clinically recognized for its reliable hypnotic efficacy.

Property Description
Active ingredient Nitrazepam
Form Oral tablet
Pharmacological class Benzodiazepine, Sedative-Hypnotic Agent
General purpose Promoting sleep and deep relaxation
Origin Synthetic compound

What Type of Medicine is Nitrazepam?

Nitrazepam is definitively classified as a sedative-hypnotic agent, a pharmacological category of medicines designed to induce sleep and promote deep relaxation. As a synthetic compound, its chemical identity is 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one. The drug is most commonly formulated for patient use as an oral tablet, which serves as the established route of administration. As a benzodiazepine derivative, it possesses a profile optimized for rapid onset and a strong hypnotic effect, distinguishing it within its class. This focus on sleep induction makes Nitrazepam a recognized choice for individuals requiring effective short-term management of sleep disturbances.

What is the General Purpose of Nitrazepam?

The general purpose of Nitrazepam is to act as a highly effective agent for promoting rest by rapidly slowing down activity within the brain. This is achieved through its primary physiological action, which involves the enhancement of natural inhibition by boosting the effects of the brain’s native calming neurotransmitter, Gamma-Aminobutyric Acid (GABA). By amplifying this natural inhibitory signal, Nitrazepam decreases the excitability of nerve signals, leading to the generalized calming and muscle relaxation necessary to achieve and maintain sleep. This powerful action defines its utility as a reliable tool for addressing the state of being unable to sleep.

What side effects are possible with Nitrazepam?

Possible Side Effects and Safety Information

Nitrazepam's safety profile, as documented in official regulatory sources, is characterized by effects primarily on the central nervous system (CNS) and psychological function. Adverse reactions are classified by frequency and system-organ class according to regulatory standards.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions, classified as Common in regulatory documents, include drowsiness, reduced alertness, fatigue, headache, dizziness, loss of coordination (ataxia), and confusion. These effects are generally noted as being more pronounced at the beginning of treatment.

Reactions classified as Rare or Frequency Not Known encompass a wider range of effects, including vertigo, visual impairments (such as double vision), muscle weakness, nausea, and various skin reactions.

Serious Safety Considerations

The official labeling explicitly documents several serious safety risks associated with Nitrazepam:

  • Dependence and Withdrawal: Both physical and psychological dependence can develop even at therapeutic doses. Abrupt discontinuation, particularly after prolonged use, is associated with the risk of a severe withdrawal syndrome, which can include seizures or psychotic manifestations.
  • Amnesia: The risk of anterograde amnesia (impaired ability to recall new information) is officially documented, with the risk increasing with higher doses.
  • Paradoxical Reactions: Reactions contrary to the drug's expected effect, such as agitation, aggression, or excitement, are noted.

Population-Specific Safety Notes

Regulatory texts include safety notes for specific populations. Older adults are at a heightened risk for CNS-related adverse reactions, which increases the potential for falls and injuries due to reduced motor coordination. Furthermore, the medicine is officially contraindicated in patients with severe hepatic insufficiency or severe respiratory insufficiency (e.g., severe sleep apnea) due to the risk of exacerbation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation defines Nitrazepam overdose primarily through a spectrum of Progressive Central Nervous System (CNS) Depression. Initial signs commonly documented include excessive drowsiness, mental confusion, slurred speech, and ataxia (lack of coordination). The progression of toxicity can lead to a stuporous state and ultimately coma.

Severe outcomes are linked to Cardiorespiratory Compromise, encompassing the risks of profound respiratory depression, marked hypotension (low blood pressure), and death, especially where the medicine has been co-ingested with other CNS depressants like alcohol.

Regulators mandate that immediate medical attention must be sought for any suspected overdose or if severe symptoms develop. This requires contacting emergency services or proceeding directly to a hospital's Emergency Department. Treatment involves providing comprehensive symptomatic and supportive care, which may include advanced procedures such as airway management and mechanical ventilation for severe cases. While the specific antagonist, Flumazenil, is available, its use is typically reserved for limited, select situations. Population-specific notes indicate that elderly patients are more susceptible to severe CNS depression, and children often present with ataxia as a primary sign.

Therapeutic Uses of Nitrazepam

What Nitrazepam Treats: Main Uses and Benefits

Nitrazepam is commonly applied across therapeutic domains involving two main symptomatic areas. It is generally used for the short-term management of severe insomnia and related sleep disturbances, and it is also applied across neurological domains where anticonvulsant support is needed in specific pediatric seizure syndromes.

This medication is used for conditions marked by significant patient distress. It specifically helps address symptom clusters that include pronounced difficulty falling asleep, frequent nighttime awakenings, and involuntary muscle jerks or spasms.

Management of Primary Therapeutic Domains

Nitrazepam is commonly used to provide symptomatic support for hypnotic benefit in the short-term management of severe insomnia, relevant when symptoms create noticeable physiological strain or interfere with daily comfort. In addition, it is applied across neurological domains to help with managing the challenging motor symptoms of specific seizure disorders in children, such as those involving infantile spasms. The use of Nitrazepam supports the patient during difficult episodes by easing distress and may assist with managing functional stability during symptomatic periods.

Quick Fact: Relief for Severe Sleep Disruption

Regulatory References

  1. Health Canada Product Monograph

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Regulatory documents establish strict criteria for who can and cannot use Nitrazepam. Use is primarily established for adult patients requiring short-term, symptomatic management of severe, disabling insomnia. All other population groups and conditions are subject to specific restrictions or absolute prohibitions as detailed in official prescribing information.

Absolute Contraindications

Nitrazepam is strictly contraindicated in patients with the following conditions, regardless of therapeutic need:

  • Severe respiratory insufficiency or respiratory depression.
  • Sleep Apnoea Syndrome.
  • Severe hepatic insufficiency (severe liver failure).
  • Myasthenia gravis (a neuromuscular disease).
  • Known hypersensitivity to nitrazepam or any other benzodiazepine.

Population and Condition Restrictions

Population Group Regulatory Status
Pediatric/Juvenile Contraindicated for use as a hypnotic (for insomnia).
Older Adults (Geriatric) Use is restricted; doses must not exceed half those for adults.
Pregnancy/Lactation Not recommended; use is generally avoided during gestation and breastfeeding.
Renal/Hepatic Impairment Restricted use in non-severe cases; requires cautious approach.
Depressive/Psychotic Illness Not recommended as a primary treatment; use requires caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Nitrazepam is defined by combinations that either enhance central nervous system (CNS) depression or alter the drug's clearance rate through hepatic metabolism, as documented in official regulatory sources.


Drug-Drug and Substance Interactions

Interaction Type Interacting Agent Official Regulatory Statement
High-Risk/Contraindicated Opioids Co-administration is subject to regulatory constraint due to the risk of profound sedation, respiratory depression, coma, and death stemming from an additive CNS depressant effect.
Exposure Enhancement Cimetidine, Oestrogen-containing contraceptives, Disulfiram Substances inhibiting hepatic metabolism can increase the plasma concentration of Nitrazepam, as its elimination half-life may be prolonged.
Efficacy Reduction Rifampicin, Caffeine, Theophylline Documented to increase hepatic metabolism (Rifampicin) or cause pharmacodynamic antagonism (Caffeine, Theophylline), thereby reducing concentration or therapeutic effect.
Pharmacodynamic Enhancement Alcohol, Antipsychotics, Other Hypnotics Use with other CNS depressants, including alcohol, is not recommended due to a reinforced central depressive effect.

Administration and Population Notes

To mitigate the risk of anterograde amnesia, regulatory guidance specifies the need for an uninterrupted sleep of 7–8 hours following ingestion. Population-specific constraints apply to the elderly and patients with chronic hepatic or renal disease, who demonstrate a prolonged elimination half-life. This extended clearance time increases the potential for greater exposure and heightened interaction effects.

Mechanism of Action

How Nitrazepam Works: Mechanism of Action

Targeting the GABA A Receptor and Chloride Flux

Nitrazepam is a positive allosteric modulator that acts on the GABA A receptor, the primary inhibitory ion channel in the central nervous system. It binds to an allosteric site distinct from the GABA binding site. This interaction potentiates the effect of GABA, increasing the frequency with which the ion channel opens, which allows greater flow of negatively charged chloride ions ( Cl^-) into the postsynaptic neuron. This influx causes neuronal hyperpolarization.


Modulating Inhibitory Tone and Neuronal Excitability

The resulting hyperpolarization creates a generalized potentiation of the inhibitory tone throughout the brain. This primarily affects the Reticular Activating System and the Limbic System pathways, resulting in a reduction in overall neuronal excitability and a shift toward an increased central inhibitory tone.


Mechanistic Cascade on Motor Control Pathways

The inhibitory action extends to the spinal cord and motor control centers. Here, the GABAergic potentiation limits the transmission of excitatory signals to the muscles. This mechanism causes inhibition of motor reflex pathways, resulting in a decrease in skeletal muscle tone.

Dosage and Administration Information

Nitrazepam is strictly administered via the oral route, typically as a tablet, though an oral suspension is approved for use in certain regions. Administration is a once-daily regimen, and the dose must be taken just before retiring to bed. Patients are instructed to ensure they can achieve seven to eight hours of uninterrupted sleep after taking the medication to align with proper usage guidelines.


Official Dosing and Duration

Population Group Labeled Dosing Regimen (Once Daily)
Standard Adults 5 mg to 10 mg, starting with the lowest effective dose.
Older Adults/Debilitated Reduced dose, typically starting at 2.5 mg and generally not exceeding 5 mg.

For standard adult dosing, an amount up to 10 mg is usual, with higher doses reserved for hospitalized cases. Doses for older and debilitated patients should not exceed half the normal adult recommended dose. Dosage adjustments may also be necessary for individuals with impaired liver or renal function.


Treatment Course Instructions

Treatment is strictly defined as short-term, typically lasting from a few days up to two weeks, and must not exceed four weeks in total, which includes the required dose reduction period. When discontinuing the medication, the dose must be progressively reduced or tapered off, as abrupt cessation is contra-indicated in standard procedural guidelines. The total duration should not be extended without a formal re-evaluation of the patient's status.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nitrazepam

Evidence for Use in Severe Sleep Disturbances (Insomnia)

Research exploring the role of this medication in the context of hypnotic activity involves short-term Randomized Controlled Trials (RCTs) and meta-analyses conducted in adult populations. Studies were used to explore how symptoms of sleep disturbance change over time. Researchers measured outcomes such as the time it takes for a person to fall asleep and the total time spent asleep. Studies described patterns observed in these short-term trials when compared to a non-active treatment (placebo). Evidence is limited regarding the durability of these observations, as the majority of trials cover only a few weeks. The data also often groups Nitrazepam with other medicines in its class.

Evidence for Anticonvulsant Support in Pediatric Seizures

The research was studied for its role in specific pediatric epileptic syndromes, such as Infantile Spasms (West Syndrome), and includes small RCTs and observational studies where infants and young children were monitored. Research examined outcomes describing episodic or acute changes by monitoring how frequently epileptic spasms occurred. Studies reported spasm frequency measured during acute follow-up periods. The evidence base is considered limited, as it often relies on older studies with modest sample sizes, meaning certainty remains low in some areas. Long-term effects related to neurodevelopmental outcomes are not fully established from primary trials.

Long-Term Studies and Extended Follow-up

Most available research is based on short, acute trials, meaning follow-up durations were limited for many key outcomes. Studies that have monitored long-term use in observational settings have explored outcomes related to systemic imbalance that may be observed over months or years. Findings indicate that changes in the measured sleep outcomes may be observed within the first two weeks of continuous use. Generally, sustained outcomes are not well-characterized by controlled trials.

Evidence in Specific Patient Groups

Studies have explored how the medicine was evaluated in specific patient groups, such as older adults. Research in this area explored differences in findings for older individuals compared to younger adults. In the case of pediatric patients, Nitrazepam was studied for specific, severe epileptic syndromes, but its use as a hypnotic was not consistently studied. For other groups, such as pregnant populations, data remain insufficient in dedicated clinical trials.

What is Still Uncertain About the Research for Nitrazepam

A key uncertainty is the lack of comparative evidence from large, modern trials directly assessing Nitrazepam against non-benzodiazepine hypnotics. Findings were mixed in older comparative studies. Furthermore, long-term effects are not fully established by controlled research. Evidence is limited regarding the durability of its effects and the potential long-term impact on daily functioning. The study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

Key Studies & References

  1. Meta-analysis of benzodiazepine use in the treatment of insomnia - CMAJ
  2. comparison of effectiveness and safety of nitrazepam versus topiramate in resistant infantile epileptic spasms syndrome: an open-label, randomized controlled trial
  3. Benzodiazepines: Uses, Dangers, and Clinical Considerations - MDPI

Frequently Asked Questions (FAQ)

Common questions about Nitrazepam (FAQ)


Q: How quickly should I feel the effects of Nitrazepam after taking it?

Nitrazepam is instructed to be taken just before going to bed. Official product information on administration timing is consistent with a rapid onset of action, supporting the instruction to take it just before retiring to bed.

Q: Do you get a hangover effect or feel groggy the next day with Nitrazepam?

Yes, residual effects can occur and may persist into the next day. Regulatory summaries note that side effects like somnolence (sleepiness), dizziness, fatigue, and impaired cognitive function are reported. These effects can contribute to what is commonly described as a 'hungover' or groggy feeling.

Q: Why do some people say Nitrazepam causes weird or vivid dreams?

Official product information notes that changes in dreaming patterns are among the possible side effects. Specifically, unpleasant dreams and depressed or increased dreaming have been reported with this medication.

Q: Is it true that Nitrazepam can lead to dependence or addiction?

Yes, both physical and psychological dependence can develop even at therapeutic doses. Official warnings state that the risk of dependence increases with the dose and the total length of time the medication is used.

Q: Can Nitrazepam affect my memory or ability to concentrate?

Official information confirms that impairment of memory, including amnesia, and impaired concentration are documented side effects. Confusion is also a commonly reported reaction to the medication.

Q: What are the most common side effects people report when taking Nitrazepam?

The most frequently reported adverse reactions, according to regulatory documents, are drowsiness, fatigue, headache, dizziness, confusion, and loss of coordination (ataxia). These effects are often more noticeable when treatment is first started.

Q: Are there any over-the-counter cold or allergy medicines that interact with Nitrazepam?

Official guidance warns against taking Nitrazepam with other central nervous system (CNS) depressants. Some over-the-counter cold or allergy medicines contain sedating substances (like certain antihistamines). Combining these with Nitrazepam may lead to a reinforced central depressive effect, such as increased drowsiness or confusion, and is generally cautioned against.

Q: Can Nitrazepam be used by elderly people, and are there special precautions?

Use in older adults is restricted and requires a reduced dosage, typically starting at half the standard adult dose. Older adults have a heightened risk for CNS-related adverse reactions. Regulatory information specifically notes this increased potential for side effects and injuries, such as falls, and mandates a reduced dosage.

Q: Does Nitrazepam help with sleep maintenance or just falling asleep?

Nitrazepam is indicated for the short-term management of insomnia, addressing both difficulty falling asleep (sleep onset) and frequent awakenings during the night (sleep maintenance). Patients are instructed to ensure they can achieve seven to eight hours of uninterrupted sleep after taking it.

Q: Why is it important to tell my doctor about all the vitamins I take before starting Nitrazepam?

The effectiveness of Nitrazepam can be altered by other substances that affect how the liver processes the drug. This is why it is important to disclose all co-administered products, including supplements and vitamins, to rule out potential interactions that could change the drug's concentration in the blood.

Q: Can a person develop a tolerance to Nitrazepam over time?

Official warnings mention that tolerance may occur. This means the hypnotic or sleep-inducing effect of the medication could be diminished after it has been used repeatedly for a few weeks.

Q: How is the effectiveness of Nitrazepam measured in studies?

Clinical trials and studies typically measure the effectiveness of the medication based on patient outcomes. These include objective measures, such as the time it takes for a person to fall asleep and the total duration of sleep.

Q: Is it normal if I feel a little confused when I wake up after taking Nitrazepam?

Confusion is listed as a common adverse reaction to this medication. Furthermore, residual effects like impaired concentration and drowsiness can carry over into the next day, which may cause a feeling of confusion upon waking.

Q: Does Nitrazepam interact with birth control pills?

Yes, official product information specifically lists oestrogen-containing contraceptives (a type of birth control pill) as an interacting agent. These substances may inhibit the body's natural processes for breaking down Nitrazepam, potentially increasing the amount of the drug in the body.

Q: What happens if I stop taking Nitrazepam suddenly after using it for a while?

Abrupt discontinuation of Nitrazepam, especially after prolonged use, is not recommended and carries the risk of a severe withdrawal syndrome. Signs of withdrawal may include rebound anxiety and insomnia, extreme tension, restlessness, and in severe cases, psychosis or seizures.

Q: How long does it typically take for Nitrazepam to be completely cleared from the body?

Nitrazepam has a long elimination half-life, averaging around 26 hours in adults. Its long half-life indicates it may take several days for the medication to be fully cleared from the system.

Q: Is there a generic version of Nitrazepam, and is it just as effective?

Nitrazepam is available as a generic product containing the same active ingredient. Regulatory agencies apply standards to ensure they are therapeutically equivalent. This means they are expected to work in the body in the same way as the brand-name version.

Q: Can Nitrazepam cause a paradoxical reaction like increased excitement or agitation?

Yes, official safety information documents the possibility of paradoxical reactions, which are effects contrary to the intended purpose of the drug. Reported examples include agitation, aggression, excitement, restlessness, and hyperactivity.

Q: Does Nitrazepam show up in breast milk, and is it a concern for nursing mothers?

Yes, regulatory and pharmacological sources confirm that the drug is excreted into breast milk. Due to its long half-life, there is a potential for the drug to accumulate in the infant's system, and its use is generally avoided during breastfeeding.

Q: What happens if I accidentally take too much Nitrazepam?

Overdose effects are documented and generally range from extreme drowsiness, uncoordinated movements, and slurred speech. In more severe cases, an overdose can depress breathing and may lead to a coma.

Q: Is Nitrazepam safe for teenagers or children with severe sleep issues?

Official product information states that Nitrazepam is strictly contraindicated for use as a hypnotic (for sleep issues) in pediatric and juvenile patients.

Q: How important is it to take Nitrazepam exactly as prescribed and not share it?

It is essential to take the medication strictly as prescribed. Because Nitrazepam is classified as a controlled substance due to the risk of dependence and misuse, it must not be shared with others and should be kept securely out of sight.

Q: What are the signs of withdrawal from Nitrazepam?

The signs of withdrawal, which can occur after sudden stopping, may include the return of severe anxiety and insomnia, along with physical symptoms such as tension, restlessness, irritability, sweating, and headache. More severe manifestations can include psychosis or seizures.

Q: Do I need to take Nitrazepam with food or on an empty stomach?

Studies on the drug’s pharmacokinetics have found that taking Nitrazepam with food has no apparent influence on how it is absorbed or its overall availability in the body. Therefore, it may be taken either with food or on an empty stomach.

Q: Does Nitrazepam affect blood pressure or heart rate?

Changes in blood pressure or heart rate are not commonly listed among the adverse effects. However, in cases of severe overdose, official safety documents note that effects such as a drop in blood pressure (hypotension) can occur.

How should Nitrazepam be stored and disposed of?

Storage Requirements

Official regulatory labeling for Nitrazepam tablets requires storage at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). The medication must be kept in the original container, protected from light, and should not be used past the printed expiry date.

Nitrazepam is classified as a Schedule IV controlled substance. Due to this status, it must be kept in a safe place and out of the sight and reach of children to prevent misuse or accidental ingestion.

Disposal Instructions

Unused or expired Nitrazepam should be disposed of according to local regulations. The preferred method is using a community drug take-back program. If a program is unavailable, FDA guidance recommends mixing the medication with an undesirable substance (such as dirt or coffee grounds), sealing it in a container, and placing it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitrazepam found in:

A-Z Index: